Management (HFA-710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857,

Daniel.Gittleson@fda.hhs.gov, 301-796-5156.

SUPPLEMENTARY INFORMATION: In the Federal Register of May 21, 2009 (74 FR 23865), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0186. The approval expires on July 31, 2012. A copy of the supporting statement for this information collection is available on the Internet at http://www.reginfo.gov/ public/do/PRAMain.

Dated: August 11, 2009.

## Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. 09-19785 Filed 8-17-09; 8:45 am] BILLING CODE 4160-01-S

## **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### Food and Drug Administration

[Docket No. FDA-2008-N-0657]

**Agency Information Collection Activities: Announcement of Office of** Management and Budget Approval; **Recommendations for Early Food** Safety Evaluation of New Non-**Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use** 

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Recommendations for Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

# FOR FURTHER INFORMATION CONTACT:

Daniel Gittleson, Office of Information Management (HFA-710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857,

Daniel.Gittleson@fda.hhs.gov 301–796– 5156.

SUPPLEMENTARY INFORMATION: In the Federal Register of April 17, 2009 (74 FR 17868), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0583. The approval expires on July 31, 2012. A copy of the supporting statement for this information collection is available on the Internet at http://www.reginfo.gov/ public/do/PRAMain.

Dated: August 11, 2009.

#### Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E9-19784 Filed 8-17-09; 8:45 am] BILLING CODE 4160-01-S

### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

# **Food and Drug Administration**

[Docket No. FDA-2009-N-0336]

## Animal Drug User Fee Rates and **Payment Procedures for Fiscal Year** 2010; Correction

**AGENCY:** Food and Drug Administration,

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration is correcting a notice entitled that appeared in the Federal Register of August 3, 2009 (74 FR 38429). The document announced the Fiscal Year 2010 fee rates for the Animal Drug User Fee Act. The document was published with a typographical error. This document corrects that error.

# FOR FURTHER INFORMATION CONTACT:

David Miller, Office of Financial Management (HFA-100), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3917.

SUPPLEMENTARY INFORMATION: In FR Doc. E9-18459, appearing on page 38429 in the **Federal Register** of Monday, August 3, 2009, the following correction is made:

1. On page 38429, in the third column, in the first sentence of the last paragraph under Background, '\$209,400'' is corrected to read "\$290,400".

Dated: August 12, 2009.

# Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

[FR Doc. E9-19779 Filed 8-17-09; 8:45 am] BILLING CODE 4160-01-S

# **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

### **National Institutes of Health**

# **National Institute of General Medical** Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel ZGM1-GDB-X-C1.

Date: September 8, 2009.

Time: 2 p.m. to 4 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Natcher Building, Room 3AN18, 45 Center Drive, Bethesda, MD 20892 (Telephone Conference Call).

Contact Person: John J. Laffan, PhD, Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN18J, Bethesda, MD 20892, 301-594-2773.

(Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS)

Dated: August 10, 2009.

# Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-19624 Filed 8-17-09; 8:45 am] BILLING CODE 4140-01-M

#### DEPARTMENT OF HEALTH AND **HUMAN SERVICES**

# **Food and Drug Administration**

[Docket No. FDA-2009-N-0247]

## **Food and Drug Administration** Transparency Task Force; Reopening of Comment Period

**AGENCY:** Food and Drug Administration, HHS.